Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04982146
Other study ID # BROAC-PMP
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date September 13, 2021
Est. completion date May 16, 2023

Study information

Verified date June 2022
Source Maimónides Biomedical Research Institute of Córdoba
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial pursues studying a compassionate treatment option for patients with inoperable pseudomyxoma peritonei through percutaneous administration of bromelain + N-acetylcysteine (NAC) in order to decrease tumoral volume. Secondary endpoints are the decrease of ascites, compressive symptoms and pain through the dilution of mucins, which would better intestinal blockage.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 10
Est. completion date May 16, 2023
Est. primary completion date May 16, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pseudomyxoma peritonei diagnosis through imaging tests and/or histological studies - Pseudomyxoma peritonei relapse in abdominal area in patients who comply inoperability criteria, which are: At least two HIPEC operations or major abdominal surgery (PSS > 3). Patients with acute morbidities (ASA score IV) - ECOG 0-2 - Age = 18 - Signs informed consent Exclusion Criteria: - Candidates to other potentially healing treatments - Allergy to bromelains (pineapple), N-Acetylcysteine or possible cross-reactive allergy (eggs, sulphate. latex, carrots, celery, wheat...) - Non-manageable coagulation alterations - No possibility of intraabdominal drainage catheter - Acute respiratory pathology (asthma, COPD), acute hepatic, cardiopathic or kidney pathology - Allergy to any substance that might cause crossed reactivity to bromelain - Unwillingness to participate in this clinical trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bromelin
0.5mg per mL of total tumor volume calculated, administered percutaneously
N-Acetylcysteine
20mg per mL of total tumor volume calculated, administered percutaneously

Locations

Country Name City State
Spain Hospital Universitario Reina Sofía Córdoba

Sponsors (1)

Lead Sponsor Collaborator
Maimónides Biomedical Research Institute of Córdoba

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumoral Mass Change Tumoral mass change calculated through CT Scan or Magnetic Resonance categorized regarding the biggest diameter per abdominal region Day 3, Day 7 (if it applies),1 month and 12 months after treatment is finished.
Secondary Symptoms improvement Symptoms progression evaluated through QLQ-C30 questionnaire (life quality questionnaire) Basal visit, 1 month and 12 months after treatment.
Secondary TTP (Time to tumor progression) Period of time free of tumor progression. Period of 12 months after treatment.
Secondary Overall survival Time until death from any cause Period of 12 months after treatment.
Secondary Tumoral DNA diminution in biological samples Diminution of tumoral DNA amount found in mucin and blood samples Basal visit, all treatment visits and 12 months after treatment is finished.
See also
  Status Clinical Trial Phase
Recruiting NCT04024917 - Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis N/A
Completed NCT02374411 - Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients N/A
Recruiting NCT02073500 - Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Active, not recruiting NCT01427101 - Results of CRS and Debulking in PMP Patients N/A
Completed NCT04088786 - Phase I Trial HIPEC With Nal-irinotecan Phase 1
Not yet recruiting NCT06084780 - Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) Phase 2
Active, not recruiting NCT02834169 - French National Registry of Rare Peritoneal Surface Malignancies N/A
Completed NCT01764789 - Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer N/A
Completed NCT02040142 - Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Phase 2
Withdrawn NCT04125225 - What Are the Experiences of Patients With Pseudomyxoma Peritonei?
Not yet recruiting NCT03976973 - BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei Phase 2
Recruiting NCT01617382 - Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
Completed NCT01652794 - Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer Phase 1
Completed NCT01126346 - Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) N/A
Completed NCT05513183 - Severe Neutropenia After HIPEC Using Mitomycin-C
Active, not recruiting NCT02834013 - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Phase 2
Recruiting NCT03210298 - International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Active, not recruiting NCT02387203 - Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Phase 2
Terminated NCT04665921 - A Study of SGN-STNV in Advanced Solid Tumors Phase 1
Recruiting NCT05321329 - Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients Phase 2